Tejaswini Baral

Tejaswini Baral

Auto-generated profile, based on publicly available information

Tejaswini Baral

Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, India

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 November 2024 in Allergy, Asthma & Clinical Immunology
Verified
Journal Article
Open access
PDF file
DBDivya Balan
Divya Balan
TBTejaswini Baral
Tejaswini Baral
MMMohan K. Manu
Mohan K. Manu
AMAswini Kumar Mohapatra
Aswini Kumar Mohapatra
SMSonal Sekhar Miraj
Sonal Sekhar Miraj
Background: Asthma is a chronic, heterogeneous disease characterized by airway inflammation. Asthma exacerbations significantly increase the disease burden, necessitating new therapeutic approaches. Emerging evidence suggests probiotics, through the gut-lung axis, may benefit asthma management by modulating immune responses and reducing inflammation. Methods: This systematic review and meta-analysis adhered to PRISMA guidelines and was registered with PROSPERO (CRD42023480098). A comprehensive search of PubMed, Scopus, Web of Science, and Embase was conducted up to March 2024. Inclusion criteria encompassed randomized controlled trials (RCTs) evaluating probiotic interventions in asthma patients. Statistical analysis was done using RevMan 5.3, with odds ratios (OR) and 95% confidence intervals (CI) calculated, and heterogeneity assessed using I2 statistics. Results: Twelve RCTs, comprising 1401 participants, met the inclusion criteria. The probiotic strains investigated included various Lactobacillus and Bifidobacterium species. Meta-analysis revealed significant improvements in asthma control test scores (OR 1.18, 95% CI: 1.18–3.64, p = 0.0001) following probiotic supplementation. Probiotics also improved fractional exhaled nitric oxide (FeNO) in one study, but pooled FeNO and eosinophil data were not statistically significant (p = 0.46 and p = 0.29, respectively). One study observed fewer asthma exacerbations in the probiotic group (24/212) compared to placebo (67/210), with no difference in exacerbation duration. Conclusion: Probiotic supplementation may be beneficial in improving asthma symptom control with no significant impact on lung function indices or eosinophil levels. Probiotics can be a potential adjunctive therapy in asthma management, particularly for asthma symptom control.

3 January 2023 in Expert Review of Anti-infective Therapy
Verified
Journal Article
Closed access
TBTejaswini Baral
Tejaswini Baral
SKShilia Jacob Kurian
Shilia Jacob Kurian
LTLevin Thomas
Levin Thomas
CKChandrashekar Udyavara Kudru
Chandrashekar Udyavara Kudru
CMChiranjay Mukhopadhyay
Chiranjay Mukhopadhyay
SMSonal Sekhar Miraj
Sonal Sekhar Miraj
This systematic review evaluates the gut microbiota (GM) status in tuberculosis (TB) patients compared to healthy volunteers due to the disease or its treatment.We conducted a systematic review of ...

31 July 2025 in Journal of the American Nutrition Association
Verified
Journal Article
Open access
TBTejaswini Baral
Tejaswini Baral
VGVARUN KUMAR S G
VARUN KUMAR S G
MMMohan K. Manu
Mohan K. Manu
CKChandrashekar Udyavara Kudru
Chandrashekar Udyavara Kudru
JSJitendra Singh
Jitendra Singh
SMSonal Sekhar Miraj
Sonal Sekhar Miraj
This study aimed to assess the effect of probiotic supplementation on multiple dimensions of tuberculosis (TB) care, including clinical, humanistic, and safety outcomes. This study is a prospective cohort study. Data were collected for TB treatment outcome, hematologic inflammatory indices, anti-tuberculosis treatment (ATT)-induced adverse drug reactions (ADRs), and health-related quality of life (HRQoL) using EuroQol 5-Dimension 5-level questionnaire to evaluate the effect of probiotics supplementation. In all, 177 patients with drug-sensitive pulmonary TB were enrolled. TB treatment success rates in the study group (SG) and the reference group (RG) were 85.1% and 84.6%, respectively (p = 1.000). Among hematologic inflammatory indices, only the systemic inflammation response index (SIRI) showed a statistically significant reduction after probiotic supplementation (p = 0.048). No significant changes were observed in HRQoL scores at various time points. ATT-induced ADRs were significantly lower in the SG than the RG (14.8% vs 61.3%; p < 0.001). Probiotic supplementation did not significantly influence TB treatment success or HRQoL outcomes. However, it showed a favorable impact on systemic inflammation and a significant reduction in the incidence of ATT-induced ADRs, especially gastrointestinal side effects. These findings suggest a potential role for probiotics as a supportive adjunct to ameliorate ATT-induced ADRs. Future studies should focus on assessing long-term supplementation effects to investigate humanistic outcomes.

1 January 2025 in Scientifica
Verified
Journal Article
Open access
TBTejaswini Baral
Tejaswini Baral
MMMohan K. Manu
Mohan K. Manu
KSKavitha Saravu
Kavitha Saravu
CKChandrashekar Udyavara Kudru
Chandrashekar Udyavara Kudru
JSJitendra Singh
Jitendra Singh
SMSonal Sekhar Miraj
Sonal Sekhar Miraj
This scoping review aims to synthesize the current clinical evidence on probiotics used in tuberculosis (TB). Systematic literature searches were conducted across PubMed, Scopus, and Embase databases to identify all studies using probiotics in TB. A total of six studies conducted between 2016 and 2023 were found and included in this review. All the studies incorporated probiotics supplementation not beyond the intensive phase of antitubercular therapy (ATT), ranging from three to eight weeks. Five out of six included studies focused on pulmonary TB. Probiotics alleviate adverse gastrointestinal and hepatic drug reactions, modulate gut microbiota, enhance barrier function, and influence immune responses. Therefore, probiotics are a potential adjunct therapy during the intensive phase of ATT. However, their long‐term effects remain unexplored, highlighting the future research scope for well‐designed longitudinal studies to explore their sustained benefits.

25 August 2020 in Journal of Pharmacy Technology
Verified
Journal Article
Closed access
PDF file
TBTejaswini Baral
Tejaswini Baral
DLD. Vijaya Laxmi
D. Vijaya Laxmi
MPMounika Pedada
Mounika Pedada
NGNeelima Krishna Veni Ganta
Neelima Krishna Veni Ganta
WFWasim Feroz
Wasim Feroz
Vitamin D deficiency is widespread, yet it is the most underdiagnosed and undertreated nutritional deficiency and has a very crucial clinical importance in today’s medical field. To assess quality of life in patients with polyarthralgia based on 25-hydroxycholecalciferol (25-(OH)D) levels, which will help understand the importance of vitamin D in a broader sense. Our panel study was carried out in the department of orthopedics of a tertiary care hospital in southern India between October 1, 2018, and February 28, 2019. A total of 114 patients with polyarthralgia from the outpatient department were included in the study. In our study, there was a predominance of female patients (77.2%). Overall, 92.10% of our study population were aged between 21 and 60 years. The highest percentage of low vitamin D status was detected in unexplained polyarthralgia cases (52.63%), who did not have any comorbid condition except a low serum level of 25-(OH)D level. There was a strong association between quality of life, before and after supplementation of vitamin D (P < .0001), for every domain of the 36-item Short Form Survey. The 36-item Short Form Survey analysis showed that the patients with polyarthralgia whose serum level of 25-(OH)D was found below the optimal range had dramatic improvement in their symptoms after vitamin D supplementation. Based on the findings of our study, we strongly recommend screening for vitamin D deficiency in those who are at risk, as features of low vitamin D are mostly reversible with proper supplementation.

29 January 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
UNUsha Nayak
Usha Nayak
TBTejaswini Baral
Tejaswini Baral
SMSonal Sekhar Miraj
Sonal Sekhar Miraj
MMMohan K Manu
Mohan K Manu
MVMuralidhar D Varma
Muralidhar D Varma
JMJyothsna Manikkath
Jyothsna Manikkath
Background: Female genital tuberculosis (FGTB) continues to be a significant problem worldwide. Endometrial biopsy (EB) is the most effective sample for detecting FGTB. However, biopsy is invasive and causes unwarranted suffering. Furthermore, a few studies have investigated non-invasively obtained menstrual blood (MB) as an alternative diagnostic sample for detecting FGTB. Hence, in this study, we are assessing MB as an alternative sample to EB for diagnosing FGTB. Method: A systematic literature search was conducted using the electronic databases PubMed, Scopus, Web of Science, and Embase until September 2024. All original studies that compared MB with samples of EB for diagnosing FGTB were included. Results: A total of nine studies were obtained. The sensitivity of tests using MB as a sample ranged from 33.3% to 91.7%, while the specificity ranged from 82.9% to 97.3%. In the EB group, the sensitivity ranged from 64.8% to 95.8%, and the specificity ranged from 84.3% to 97.5%. Conclusion: The review suggests that MB could be a potential sample for diagnosing FGTB, as the specificity of tests using this sample is comparable to that from the EB group. PROSPERO registration: The study protocol was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the identification number CRD42024509199.